Biomedical Engineering Reference
In-Depth Information
Table 10.2
Published Clinical Studies on ALA- and MAL-PDT for Bowen's Disease (
Continued
)
MAL-PDT Study
Design
Incubation
Period (hr)
# Lesions Treated
(# patients)
Light Source
(wavelength in nm)
Reference
Location of BD
Response Rate
Follow-up (mo)
Morton (119) (2006)
MAL-PDT
(2 sessions 1 wk
apart) vs.
placebo-PDT vs.
cryotherapy vs.
5-FU for 4 wk;
repeated at 3 mo if
required
Face, scalp, trunk,
and limbs
3
275 (124 treated
with MAL-PDT)
in 225 patients
Broadband red light
(570-670 nm,
75 J/cm
2
)
MAL-PDT-
80% CR vs.
placebo-PDT
10% CR vs.
cryotherapy
67% CR vs.
5-FU 69% CR
12
Morton (120) (2005)
MAL-PDT
(2 sessions 1 wk
apart) vs.
placebo-PDT vs.
cryotherapy vs.
5-FU for 4 wk;
repeated at 3 mo
if required
Face, scalp, trunk,
and limbs
3
275 (124 treated
with MAL-PDT)
in 225 patients
Broadband red light
(570-670 nm,
75 J/cm
2
)
MAL-PDT-68% CR
vs. placebo-PDT
11% CR vs.
cryotherapy
60% CR vs.
5-FU 59% CR
24
Abbreviations
: ALA, aminolevulinic acid; BD, Bowen's disease; MAL, methyl aminolevulinic acid; PDT, photodynamic therapy; 5-FU, 5-fl uorouracil; CR, clearance rate.
